Literature DB >> 20368502

Is (pro)renin receptor a multifunctional receptor?

Qiuhong Li, Mohan K Raizada.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20368502      PMCID: PMC2874102          DOI: 10.1161/HYPERTENSIONAHA.110.151142

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  17 in total

1.  Suppression of ocular inflammation in endotoxin-induced uveitis by inhibiting nonproteolytic activation of prorenin.

Authors:  Shingo Satofuka; Atsuhiro Ichihara; Norihiro Nagai; Kenji Yamashiro; Takashi Koto; Hajime Shinoda; Kousuke Noda; Yoko Ozawa; Makoto Inoue; Kazuo Tsubota; Fumiaki Suzuki; Yuichi Oike; Susumu Ishida
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-06       Impact factor: 4.799

Review 2.  Physiology of local renin-angiotensin systems.

Authors:  Martin Paul; Ali Poyan Mehr; Reinhold Kreutz
Journal:  Physiol Rev       Date:  2006-07       Impact factor: 37.312

3.  Identification and characterization of a novel 9.2-kDa membrane sector-associated protein of vacuolar proton-ATPase from chromaffin granules.

Authors:  J Ludwig; S Kerscher; U Brandt; K Pfeiffer; F Getlawi; D K Apps; H Schägger
Journal:  J Biol Chem       Date:  1998-05-01       Impact factor: 5.157

4.  Human prorenin has "gate and handle" regions for its non-proteolytic activation.

Authors:  Fumiaki Suzuki; Makoto Hayakawa; Tsutomu Nakagawa; Uddin Mohammad Nasir; Akio Ebihara; Atsushi Iwasawa; Yuichi Ishida; Yukio Nakamura; Kazuo Murakami
Journal:  J Biol Chem       Date:  2003-04-08       Impact factor: 5.157

5.  RILLKKMPSV influences the vasculature, neurons and glia, and (pro)renin receptor expression in the retina.

Authors:  Jennifer L Wilkinson-Berka; Ronen Heine; Genevieve Tan; Mark E Cooper; Kate M Hatzopoulos; Erica L Fletcher; Katrina J Binger; Duncan J Campbell; Antonia G Miller
Journal:  Hypertension       Date:  2010-04-05       Impact factor: 10.190

Review 6.  Prorenin receptor blockers: effects on cardiovascular complications of diabetes and hypertension.

Authors:  Atsuhiro Ichihara; Yuki Kaneshiro; Fumiaki Suzuki
Journal:  Expert Opin Investig Drugs       Date:  2006-10       Impact factor: 6.206

Review 7.  The (pro)renin receptor: pathophysiological roles in cardiovascular and renal pathology.

Authors:  Geneviève Nguyen
Journal:  Curr Opin Nephrol Hypertens       Date:  2007-03       Impact factor: 2.894

8.  (Pro)renin receptor peptide inhibitor "handle-region" peptide does not affect hypertensive nephrosclerosis in Goldblatt rats.

Authors:  Dominik N Muller; Bernd Klanke; Sandra Feldt; Nada Cordasic; Andrea Hartner; Roland E Schmieder; Friedrich C Luft; Karl F Hilgers
Journal:  Hypertension       Date:  2008-01-22       Impact factor: 10.190

9.  Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide.

Authors:  Sandra Feldt; Wendy W Batenburg; Istvan Mazak; Ulrike Maschke; Maren Wellner; Heda Kvakan; Ralf Dechend; Anette Fiebeler; Celine Burckle; Aurelie Contrepas; A H Jan Danser; Michael Bader; Genevieve Nguyen; Friedrich C Luft; Dominik N Muller
Journal:  Hypertension       Date:  2008-01-22       Impact factor: 10.190

10.  Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy.

Authors:  A H Danser; M A van den Dorpel; J Deinum; F H Derkx; A A Franken; E Peperkamp; P T de Jong; M A Schalekamp
Journal:  J Clin Endocrinol Metab       Date:  1989-01       Impact factor: 5.958

View more
  2 in total

1.  Prorenin receptor acts as a potential molecular target for pancreatic ductal adenocarcinoma diagnosis.

Authors:  Arivajiagane Arundhathi; Wen-Han Chuang; Jen-Kun Chen; Shin-E Wang; Yi-Ming Shyr; Jiun-Yu Chen; Wei-Neng Liao; Hsin-Wei Chen; Yi-Min Teng; Chiao-Chih Pai; Chih-Hong Wang
Journal:  Oncotarget       Date:  2016-07-13

2.  Inhibitory Potential of Shen-Shuai-Ling Formulation on Renal Interstitial Fibrosis via Upregulation of PLZF.

Authors:  Na Song; Haitao Tu; Ying Li; Weijian Xiong; Ling Zhang; Hong Liu; Weisen Ding; Mei Long; Dewei Ren; Jin Zhong
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-31       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.